Combination Therapy for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is to find out whether adding the study drug atezolizumab and stereotactic body radiotherapy (SBRT) to standard treatment with abiraterone acetate, prednisone, and Lupron® (leuprolide) is a safe and effective way to treat previously untreated metastatic prostate cancer, and to see whether the study treatment works better than the standard treatment.
Will I have to stop taking my current medications?
The trial requires that participants stop taking anti-androgens like bicalutamide (Casodex) before starting the study. Other medications are not specifically mentioned, so it's best to discuss your current medications with the study team.
Is the combination therapy for prostate cancer safe for humans?
The combination of abiraterone acetate with prednisone and enzalutamide has been studied for safety in patients with metastatic castration-resistant prostate cancer. These treatments are generally considered safe, but they can have side effects, and their tolerability may vary among individuals.12345
How is the combination therapy of Abiraterone, Atezolizumab, and Enzalutamide unique for prostate cancer?
This combination therapy is unique because it combines Abiraterone and Enzalutamide, which target androgen receptors (proteins that bind male hormones), with Atezolizumab, an immunotherapy drug that helps the immune system attack cancer cells. This approach aims to address resistance mechanisms in prostate cancer by using both hormonal and immune system strategies.14678
What data supports the effectiveness of the drug combination therapy for prostate cancer?
Who Is on the Research Team?
Dana Rathkopf, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
Men over 18 with untreated metastatic hormone-sensitive prostate cancer, who can consent to treatment and have normal organ function. They must be eligible for SBRT, have an ECOG status of 0 or 1, and agree to use birth control during the study. Exclusions include HIV/HBV/HCV infection, large prostate volume (>80cc), certain allergies, other recent cancers or treatments, uncontrolled conditions like hypertension or infections.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive treatment with atezolizumab, abiraterone acetate, prednisone, GnRH analog, and SBRT
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Abiraterone
- Atezolizumab
- Enzalutamide
- Stereotactic Body Radiotherapy (SBRT)
Abiraterone is already approved in United States, European Union, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Genentech, Inc.
Industry Sponsor
Ashley Magargee
Genentech, Inc.
Chief Executive Officer since 2024
MBA from Harvard University, BA from Princeton University
Levi Garraway
Genentech, Inc.
Chief Medical Officer since 2021
MD, PhD
Stand Up To Cancer
Collaborator